[Effectiveness of lasolvan in patients with chronic obstructive bronchitis and non-atopic bronchial asthma].
OBJECTIVE
To define efficiency and mechanisms of action of mucoregulator lasolvan.


METHODS
Lasolvan treatment was given to 50 patients with chronic nonspecific pulmonary diseases (CNPD). External respiration function (ERF) and viscosity of sputum were examined on Bodyscreen II and viscosimeter Reotest 2, respectively.


RESULTS
Maximum effect was achieved on day 2-3 of lasolvan treatment: resistance of airways decreased 1.5-fold, forced pulmonary capacity and peak expiration flow increased. ERF improvement was associated with subjective improvement. Mean sputum viscosity remained unchanged. Reduction of minimal viscosity was found after the first intake of lasolvan. Later, maximal viscosity was higher in most of the patients. By day 7-10 amount of the sputum discharged forn 24 hours rose while maximal viscosity fell.


CONCLUSIONS
Lasolvan is an effective mucoregulator which perfectly improves rheologic properties of bronchial secretion. Its ability to eliminate pathological bronchial secretion from small bronchi is of special importance. This allows to use lasolvan for prevention of cor pulmonale in CNPD patients.
Aleksa
V I
VI
Prozorova
V K
VK
Mal'tseva
N A
NA
Shatikhina
L N
LN
D000328:Adult; D000551:Ambroxol / Q000008:administration & dosage / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D002908:Chronic Disease; D005100:Expectorants / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D008875:Middle Aged; D013997:Time Factors
D005100:Expectorants; D000551:Ambroxol